Prevention of Osteoporosis in Breast Cancer Survivors

NACompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

April 1, 2002

Primary Completion Date

December 1, 2007

Study Completion Date

December 1, 2007

Conditions
Postmenopausal Osteoporosis
Interventions
OTHER

Strength/Weight Training & Drug/Supplement

G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.

COMBINATION_PRODUCT

Drug/Supplement only

G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.

Trial Locations (4)

68849-4510

University of Nebraska Medical Center, College of Nursing, Kearney

68588-0220

University of Nebraska Medical Center, College of Nursing, Lincoln

68198-5330

University of Nebraska Medical Center, College of Nursing, Omaha

69361-4939

University of Nebraska Medical Center, College of Nursing, Scottsbluff

All Listed Sponsors
collaborator

National Institute of Nursing Research (NINR)

NIH

lead

University of Nebraska

OTHER

NCT00567606 - Prevention of Osteoporosis in Breast Cancer Survivors | Biotech Hunter | Biotech Hunter